Updated hourlyHourly refreshMon, Oct 26, 2026
Press Release Database
Recent press releases, indexed by topic.
Biotech & pharma
The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024) RAP-219–treated patients had a 15.4-point mean reduction in YMRS total score from baseline at Week 3 All 11 items measured by the … Continue reading "Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania"
Oct 20 · 10:15·PressReach
AI · Healthcare
WELL appoints recognized privacy and healthcare law expert Samara Starkman as Chief Privacy Officer and Vice President, Legal & Regulatory, to lead enterprise privacy, AI governance and healthcare regulatory strategy across the organization.Ms. Starkman previously led the privacy department at Cancer Care Ontario (now part of Ontario Health), co-founded INQ Consulting and was a Partner at INQ Law, advising major Ontario hospitals, pharmaceutical and health-tech companies. Ms. Starkman's...
Oct 20 · 10:00·Newsfile
Healthcare · Biotech & pharma
Tuesday 20 October, 2026
Aachen, Germany, 20 October 2026 –
The investigational compound has a unique mechanism of action that selectively engages with the NOP receptor and may represent a first-in-class therapy option for acute moderate to severe pain. Earlier this year, the investigational compound was shown to be safe and well-tolerated in a Phase I trial, supporting progression to Phase II.[1]
KF7040-21 is a randomised, double-blind, placebo- and active-controlled Phase II trial comprising a Proof of Concept (PoC) phase and a dose-ranging phase. Overall, up to 400 participants are expected to be enrolled. Initially, 96 participants will be included in the PoC phase. Following completion of this phase, an interim analysis will inform the decision to proceed to the dose-ranging phase, in which up to 304 additional participants may be enrolled to compare three dose levels of the investigational compound with placebo and an active comparator. Further information can be found on clinicaltrials.gov.
“The start of this Phase II trial is an important step in our efforts to provide patients living with pain with novel treatment options,” says Uli Brödl, Chief Scientific Officer at Grünenthal. “By selectively activating the nociceptin receptor, our investigational compound may offer a differentiated approach to deliver safe and effective pain relief.”
About Bunionectomy
Bunionectomy is accepted by regulatory authorities as a postoperative hard (bony) tissue pain model in which the analgesic effect of an investigational compound may be evaluated as a treatment for acute pain.[3]
About the NOP Receptor
Although the NOP receptor shares some sequence identity (~60%) with the opioid receptors μ-OP (MOP), κ-OP (KOP), and δ-OP (DOP), it possesses little or no affinity for opioid peptides or morphine-like compounds. Likewise, opioid receptors possess little affinity towards NOP's endogenous ligand nociceptin.[6]
About Grünenthal
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion.
For further information, please contact:
Christopher Jansen, Global Communications at Grünenthal
christopher.jansen@grunenthal.com
[1] Grünenthal Data on File
[2] my.clevelandclinic.org (accessed 23 June 2026)
[3] Singla et al. Bunionectomy as an Acute Postoperative Pain Model: Overview of Common Experimental Methods, and Insights from Past Clinical Trials. Journal of Pain Research 2024; 17: 4399-4420.
[4] Henderson G, McKnight AT. The orphan opioid receptor and its endogenous ligand-- nociceptin/orphanin FQ. Trends in Pharmacological Sciences 1997; 18 (8): 293–300.
[5] Lin AP, Ko MC. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci. 2013; 4(2): 214-24.
[6] Butour et al. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. European Journal of Pharmacology 1997; 321(1): 97–103.
Oct 20 · 09:09·Pressat
Biotech & pharma
Dublin, Oct. 20, 2026 -- "PARP Inhibitor Biomarkers Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2026 To 2034" has been added to ResearchAndMarkets.com's offering.
Oct 20 · 09:07·GlobeNewswire
Finance · Healthcare
REYKJAVIK, Iceland and LONDON, Oct. 20, 2026 — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-ryvk), Alvotech’s biosimilar to Humira® (adalimumab). The FDA … Continue reading "Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch"
Oct 20 · 08:45·PressReach
Healthcare · Biotech & pharma
Dublin, Oct. 20, 2026 -- "Human Neuregulin Molecular Reagent Market in Germany" has been added to ResearchAndMarkets.com's offering.
Oct 20 · 08:11·GlobeNewswire
Healthcare · Biotech & pharma
Dublin, Oct. 20, 2026 -- "Bioconjugation Market in the Netherlands" has been added to ResearchAndMarkets.com's offering.
Oct 20 · 08:10·GlobeNewswire
AI · Biotech & pharma
Dublin, Oct. 20, 2026 -- "Single Use Assemblies Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
Oct 20 · 08:09·GlobeNewswire
AI · Biotech & pharma
Dublin, Oct. 20, 2026 -- "Single-use Bioprocessing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
Oct 20 · 08:05·GlobeNewswire
AI · Biotech & pharma
Dublin, Oct. 20, 2026 -- "Flow Cytometry Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
Oct 20 · 08:04·GlobeNewswire